The EPS beat is small and the company remains pre-revenue with accelerating cash burn. Watch for IND clearance news in Q2 2026 — that is the next binary catalyst. The stock is unlikely to move significantly on this quarter's numbers alone; the Phase 1b extension data in Q4 2026 is the real catalyst.
Price Chart
Executive Summary
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pre-revenue biotech. The company highlighted progress in its Phase 1b Parkinson's study and expects FDA IND clearance in Q2 2026, with Phase 2 starting in Q3 2026. Cash burn remains the key concern — cash dropped from $20.8M to $16.5M in the quarter, giving roughly 2-3 quarters of runway at current burn rates.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.13 vs consensus -$0.14 (beat by 7.1%)
- Net loss $5.6M vs $4.5M in Q1 2025 (loss widened 23.8%)
- Cash & equivalents $16.5M, down from $20.8M at Dec 2025 (burn $4.3M in quarter)
- R&D expenses $2.8M (up 22.4% YoY); G&A $2.6M (up 22.6% YoY)
- Phase 1b extension data expected Q4 2026; IND clearance expected Q2 2026
- Phase 2 trial expected to begin Q3 2026
Financial Impact
Cash burn of ~$4.3M per quarter; $16.5M cash provides ~3-4 quarters runway
Risk Factors
- Cash runway limited to ~3-4 quarters — likely needs financing before Phase 2 data
- Pre-revenue biotech with no approved products; clinical trial risk
- Phase 1b extension data not expected until Q4 2026 — long wait for catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.20 (−30.23%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.20 (−30.23%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.20 (−41.75%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.20 (−27.71%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.20 (−40.89%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.20 (−40.89%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.20 (−34.07%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.20 (−34.07%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.20 (−31.82%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.20 (−36.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers